Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company specializing in the development of novel prescription medicines sustainably derived from natural plant sources in rainforest areas. The company's primary focus is on addressing gastrointestinal (GI) distress in both humans and animals, with an emphasis on chronic debilitating diarrhea and associated symptoms such as urgency, bowel incontinence, and cramping pain.
Jaguar Health operates through several subsidiaries, including Napo Pharmaceuticals, Inc., which develops and commercializes proprietary human GI pharmaceuticals globally. One of its flagship products, Mytesi® (crofelemer), is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company’s lead animal prescription drug candidate, Canalevia™, targets forms of diarrhea in dogs, while Equilevia™ supports total gut health in equine athletes.
In addition, Jaguar Health, through its Napo Pharmaceuticals subsidiary, is advancing the development of crofelemer with the ongoing OnTarget study, a pivotal Phase 3 clinical trial aimed at the preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Crofelemer has also been designated an Orphan Drug by the FDA and European Medicines Agency for short bowel syndrome (SBS) and microvillus inclusion disease (MVID).
Jaguar Health’s commitment to cancer supportive care is showcased through its preparation to launch Gelclair®, an FDA-approved oral mucositis prescription product, in Q3 2024. This initiative is part of their broader strategy to support cancer patients facing severe treatment side effects.
Beyond GI distress, Jaguar Health has a joint venture called Magdalena Biosciences, in collaboration with Filament Health Corp. This venture focuses on developing plant-based prescription medicines for mental health indications. A recent out-licensing agreement with Magdalena includes a botanical drug candidate for potential schizophrenia and psychoses indications.
Jaguar Health’s financial performance reflects consistent growth, with Q1 2024 revenue at approximately $2.4 million, showing a 20% increase from Q1 2023. Despite operational losses, the company continues to invest in research and development, particularly for rare disease treatments.
For more information, visit Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics, and Magdalena Biosciences. Stay connected with Jaguar Health on LinkedIn, X (formerly Twitter), and Instagram.
Jaguar Health (NASDAQ:JAGX) announced that Jordan's Industrial Property Protection Directorate has issued a new patent to Napo Pharmaceuticals for methods of treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal using crofelemer. This patent strengthens Jaguar's intellectual property protection for its core rare disease target indication of SBS.
Jaguar is supporting independent investigator-initiated proof-of-concept studies for crofelemer in SBS and microvillus inclusion disease (MVID) across the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025. These studies could potentially support early patient access to crofelemer in specific EU countries.
Napo currently holds approximately 173 patents and 60 patents pending. Crofelemer is the only oral plant-based prescription medicine approved under the FDA's Botanical Guidance, providing additional exclusivity advantages.
Jaguar Health (NASDAQ:JAGX) announced that Dr. Eduardo Zimmer, a key collaborator with their joint venture Magdalena Biosciences, has received the prestigious Blas Frangione Early Career Achievement Award for 2024. This award recognizes early career researchers in Alzheimer's and dementia research. Magdalena, approximately 40% owned by Jaguar, is focused on developing novel, natural prescription psychoactive medicines from plants for mental health indications.
Magdalena recently initiated preclinical studies in Brazil to evaluate two botanical drug candidates for treating depression, anxiety, ADHD, and other neuropsychiatric conditions in adults. These studies use FDG PET scans to assess differential neuronal activity, with analysis performed by Dr. Zimmer's consultancy. The research aims to determine optimal dosing and therapeutic indications for potential future FDA approval as botanical drugs.
Jaguar Health (NASDAQ:JAGX) announced that Hong Kong's Intellectual Property Department has issued a new patent to Napo Pharmaceuticals, a Jaguar family company, for methods of treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal using crofelemer. This patent strengthens Jaguar's IP protection for its core rare disease target indication of SBS.
Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for SBS and microvillus inclusion disease (MVID) in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025. These studies could potentially support early patient access to crofelemer in specific EU countries.
Napo currently holds approximately 172 patents and 61 patents pending. Crofelemer is the only oral plant-based prescription medicine approved under the FDA's Botanical Guidance, providing additional exclusivity advantages.
Jaguar Health has reported its Q2 2024 financial results, highlighting a 16% increase in combined net revenue to $2.72 million compared to Q1 2024. The revenue also saw a 2% growth compared to Q2 2023. Jaguar noted a decrease in various expenses and a significant decrease in net loss attributable to shareholders by 28% from $12.1 million in Q2 2023 to $9.5 million in Q2 2024. The company is set to launch its third prescription product, Gelclair, in October 2024 and is conducting pivotal phase 3 OnTarget trials of crofelemer for cancer therapy-related diarrhea. Additionally, an import permit for crofelemer was granted for trials in Abu Dhabi for pediatric patients with microvillus inclusion disease and short bowel syndrome.
The company will host an investor webcast on August 13, 2024, to discuss these updates.
Jaguar Health (NASDAQ:JAGX) has announced an upcoming investor webcast on August 13, 2024, at 8:30 AM Eastern Time. The webcast will cover Q2 2024 financial results and provide updates on the Phase 3 OnTarget trial, which showed clinically meaningful results for breast and lung cancer patients. Jaguar plans to explore approval pathways for crofelemer in these cancer types based on the trial outcomes. The company will file its Q2 2024 Earnings Report on Form 10-Q on the same day. Investors can register for the webcast through a provided link, and a replay will be available on Jaguar's website afterward.
Jaguar Health (NASDAQ:JAGX) has announced plans to explore an approval pathway for crofelemer in breast and lung cancer based on Phase 3 OnTarget trial results. The company will host a webcast on August 13, 2024, to review Q2 earnings and discuss the trial's clinically meaningful results. Key highlights include:
1. Crofelemer showed promising results for cancer therapy-related diarrhea (CTD) in breast and lung cancer patients.
2. An import permit was granted for a proof-of-concept trial of crofelemer in pediatric patients with rare diseases in Abu Dhabi.
3. Two independent studies on crofelemer for IBS-D have been accepted for presentation at a scientific meeting.
4. Jaguar is pursuing development for rare and orphan diseases, including MVID and SBS.
5. The company is also exploring plant-based medicines for mental health disorders through its Entheogen Therapeutics Initiative.
Jaguar Health (NASDAQ:JAGX) announced that Dr. Elaine Elisabetsky, a member of their Mental Health Entheogen Therapeutics Initiative, will speak at the University of Illinois Chicago College of Pharmacy on August 2, 2024. Her talk will cover decades of research on plant-based medicines for managing schizophrenia.
Dr. Elisabetsky is also an advisor to Magdalena Biosciences, a joint venture between Jaguar and Filament Health. Jaguar recently out-licensed a botanical drug candidate for schizophrenia and psychoses to Magdalena Biosciences. This candidate, sourced from a medicinal plant with traditional use, shows antipsychotic activity with a unique mechanism of action.
The global schizophrenia treatment market, valued at $8.29 billion in 2024, is projected to reach $13.41 billion by 2032. Schizophrenia affects about 1% of the U.S. population, with up to 34% of patients not responding to current treatments.
Jaguar Health (NASDAQ:JAGX) announced positive results from two investigator-initiated studies of crofelemer, its plant-based oral drug, for chronic refractory diarrhea in IBS-D patients. The data will be presented at the American College of Gastroenterology Annual Scientific Meeting in October 2024. Key findings include:
1. In functional diarrhea: Crofelemer significantly decreased stool consistency and abdominal pain without major side effects in a small crossover study of 18 patients.
2. In chronic idiopathic diarrhea: Nearly 60% of patients showed improvement within a 4-week treatment period.
These results suggest crofelemer's potential efficacy in treating subgroups of IBS-D, addressing an unmet need in gastroenterology. The company plans to continue investigating crofelemer for IBS-D management.
Jaguar Health (NASDAQ:JAGX) announced that its subsidiary, Napo Pharmaceuticals, has been granted a new European patent for treating diarrhea associated with congenital diarrheal disorders (CDDs) using crofelemer, a plant-based drug. This patent strengthens Jaguar's intellectual property protection for its core rare disease target indication, particularly for microvillus inclusion disease (MVID), an ultrarare CDD.
The company is supporting investigator-initiated proof-of-concept studies for crofelemer in treating short bowel syndrome (SBS) and MVID across the US, EU, and Middle East/North Africa regions. Results are expected by the end of 2024 and throughout 2025. Jaguar now holds approximately 200 patents issued and pending, with crofelemer being the only oral plant-based prescription medicine approved under the FDA's Botanical Guidance.
Jaguar Health (NASDAQ:JAGX) announced results from its Phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy. The trial did not meet its primary endpoint across all tumor types. However, it revealed clinically relevant signals for crofelemer in prespecified subgroups of patients with breast and respiratory cancer, including lung cancer. These subgroups comprised over 75% of trial participants.
Key takeaways:
- Trial included 10 tumor types and 24 targeted agents
- Positive signals improved over the initial 12-week phase
- Crofelemer was well-tolerated with an adverse event profile similar to placebo
- Company plans to engage with FDA after full data review
Jaguar will host an investor webcast on July 23, 2024, to provide updates on its cancer supportive care portfolio.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
What is Jaguar Health, Inc.?
What are the main products of Jaguar Health?
What is Mytesi® used for?
What is the OnTarget study?
What recent achievements has Jaguar Health made?
What is the focus of Magdalena Biosciences?
What are the financial highlights for Jaguar Health in Q1 2024?
What sustainability practices does Jaguar Health follow?
How can I stay updated on Jaguar Health's developments?
What is Gelclair® and its use?
